Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...

A Kalamazoo Township police officer and a suspect were hurt after shots were fired in Kalamazoo on Thursday, according to the ...

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

We will leave the Christmas movie scripting to the experts over at Hallmark, but what would a storybook ending look like for ...

I have a bit of a bag obsession. It’s gotten to the point where I have bags full of bags. Whether it’s for travel, hiking, or ...

Join the staff of White Violet Center for Eco-Justice and others as they host the upcoming Alpaca Yoga, scheduled to take ...